Royalty Pharma plc (NASDAQ:RPRX) Holdings Boosted by Regal Partners Ltd

Regal Partners Ltd increased its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 21.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,435,956 shares of the biopharmaceutical company's stock after buying an additional 258,355 shares during the quarter. Royalty Pharma comprises 3.7% of Regal Partners Ltd's holdings, making the stock its 9th largest position. Regal Partners Ltd owned 0.24% of Royalty Pharma worth $36,631,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of RPRX. Adage Capital Partners GP L.L.C. lifted its position in Royalty Pharma by 42.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 16,968,321 shares of the biopharmaceutical company's stock valued at $432,862,000 after buying an additional 5,069,127 shares during the last quarter. Swedbank AB increased its stake in Royalty Pharma by 10.3% during the 4th quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company's stock worth $310,308,000 after buying an additional 1,136,800 shares during the period. Geode Capital Management LLC increased its stake in Royalty Pharma by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 7,312,551 shares of the biopharmaceutical company's stock worth $186,846,000 after buying an additional 46,765 shares during the period. Norges Bank purchased a new position in Royalty Pharma in the 4th quarter valued at approximately $124,498,000. Finally, Northern Trust Corp grew its stake in shares of Royalty Pharma by 12.8% in the fourth quarter. Northern Trust Corp now owns 3,330,429 shares of the biopharmaceutical company's stock worth $84,959,000 after acquiring an additional 376,619 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.

Analysts Set New Price Targets

Separately, Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a research note on Friday, March 28th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $42.50.

Royalty Pharma Stock Down 0.4 %

Shares of NASDAQ:RPRX traded down $0.14 during trading hours on Monday, reaching $32.76. The stock had a trading volume of 1,774,511 shares, compared to its average volume of 3,251,391. Royalty Pharma plc has a 1 year low of $24.05 and a 1 year high of $34.20. The firm's 50 day moving average is $32.46 and its 200-day moving average is $29.61. The stock has a market capitalization of $18.88 billion, a price-to-earnings ratio of 22.57, a P/E/G ratio of 2.31 and a beta of 0.49. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Research analysts predict that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be paid a $0.22 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $0.88 annualized dividend and a yield of 2.69%. Royalty Pharma's dividend payout ratio is currently 60.69%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.